AbbVie
ABBV
$254.49
+0.04%
AbbVie is a global pharmaceutical company focused on immunology, oncology, neuroscience, and aesthetics, with key products including Skyrizi, Rinvoq, Botox, and Imbruvica. Spun off from Abbott in 2013, it has established itself as a leading biopharma player through strategic acquisitions like Allergan (2020), Cerevel, and ImmunoGen (2024). The current investor narrative centers on AbbVie's successful transition beyond Humira, driven by rapid growth of Skyrizi and Rinvoq, recent pipeline-enhancing deals such as the $10.9 billion Apogee Therapeutics acquisition, and its status as a Dividend King with a strong dividend growth trajectory.…
ABBV
AbbVie
$254.49
Related headlines
ABBV 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on AbbVie's 12-month outlook, with a consensus price target around $266.57 and implied upside of +4.8% versus the current price.
Average Target
$266.57
0 analysts
Implied Upside
+4.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$200 - $328
Analyst target range
AbbVie is covered by 28 analysts, with a consensus recommendation of 'Buy' (mean rating 1.74 on a 1-5 scale, where 1 is Strong Buy). The average price target is $266.57, implying approximately 9.2% upside from the current price of $244.11. The distribution leans heavily bullish, with no sell ratings and recent upgrades from firms like UBS (Neutral) and BMO Capital (Outperform) reaffirming positive sentiment. The target range spans from $200.00 (low) to $328.00 (high), representing a 64% spread between low and high, indicating moderate uncertainty. The high target of $328 assumes successful pipeline execution (Apogee deal, Skyrizi/Rinvoq expansion) and margin recovery, while the low target of $200 factors in potential FDA setbacks (e.g., TrenibotE rejection) or slower Humira erosion offset. Recent institutional ratings show consistent bullishness, with firms like JP Morgan, RBC Capital, and B of A Securities maintaining Overweight/Buy ratings. The wide spread suggests that while the consensus is positive, there is debate about the pace of growth and integration risks from recent acquisitions.
Drowning in data?
Find the real signal!
Bulls vs Bears: ABBV Investment Factors
AbbVie presents a compelling bull case driven by accelerating revenue growth from Skyrizi and Rinvoq, a discounted forward P/E relative to peers, and robust free cash flow that supports its Dividend King status. The analyst consensus is bullish with a 9.2% average upside. However, bearish concerns include a distorted trailing P/E, negative equity from acquisition debt, and recent FDA setbacks. The single most important tension is whether AbbVie can sustain its growth momentum and margin recovery to justify its forward valuation. If earnings expand as expected, the stock is undervalued; if growth disappoints or debt costs rise, the stock could face significant downside. Currently, the bull case has stronger evidence given the strong operational performance and reasonable forward valuation.
Bullish
- Skyrizi and Rinvoq Driving Growth: Skyrizi revenue of $4.483B and Rinvoq revenue of $2.119B in Q1 2026 are the primary growth drivers, offsetting Humira erosion ($688M). Combined, these immunology assets now dominate the portfolio and are growing rapidly.
- Forward P/E Discount to Peers: Forward P/E of 14.99x is a 32% discount to the Drug Manufacturers industry average of ~22x. This suggests the stock is undervalued relative to peers, especially given its superior revenue growth of 12.4% YoY.
- Strong Free Cash Flow Generation: TTM free cash flow of $20.865 billion easily covers dividends ($3.086B paid in Q1 2026) and capex ($265M). This robust cash generation supports the company's Dividend King status and future investments.
- Analyst Consensus Buy with Upside: 28 analysts rate ABBV a Buy (mean 1.74 on 1-5 scale) with an average target of $266.57, implying 9.2% upside. The high target of $328 suggests significant potential if pipeline execution succeeds.
Bearish
- Trailing P/E Distorted by Low Earnings: Trailing P/E of 96.41x is extremely high due to depressed net income ($699M in Q1 2026). While forward P/E is lower, the gap highlights earnings volatility and the risk of margin compression.
- Negative Shareholder Equity: Debt-to-equity of -21.12x and negative equity result from large acquisitions (Allergan, Cerevel, ImmunoGen). This financial structure increases risk, especially if interest rates remain high.
- High Debt and Interest Expense: Interest expense of $717M in Q1 2026 and a current ratio of 0.67x indicate liquidity pressure. While interest coverage of 6.6x is manageable, high debt limits financial flexibility.
- FDA Rejection for TrenibotE: AbbVie received an FDA rejection for TrenibotE due to manufacturing issues. Although not a scientific failure, it delays a potential growth driver and highlights regulatory risk.
ABBV Technical Analysis
AbbVie is in a sustained uptrend, with a 1-year price change of +30.97% and the stock currently trading at $244.11, approximately 93.3% of its 52-week range ($184.63–$261.64). This positioning near the upper end of the range suggests strong bullish momentum, though it also raises caution about potential overextension. The stock's beta of 0.283 indicates significantly lower volatility than the market, making it a defensive holding. Short-term momentum is accelerating sharply, with 1-month and 3-month price changes of +10.16% and +16.80%, respectively, outpacing the 1-year trend. This divergence signals a recent catalyst-driven surge, likely tied to the Apogee acquisition and positive pipeline news, rather than a broad trend reversal. The relative strength versus the S&P 500 over 1 month (9.56%) and 3 months (10.51%) confirms strong outperformance. Key support lies near the 52-week low of $184.63, while resistance is at the 52-week high of $261.64. A breakout above $261.64 would signal continued upside momentum, while a breakdown below $184.63 would indicate a bearish reversal. Given the low beta, AbbVie offers a smoother ride than the broader market, but its recent rapid ascent may invite profit-taking.
Beta
0.28
0.28x market volatility
Max Drawdown
-19.2%
Largest decline past year
52-Week Range
$185-$262
Price range past year
Annual Return
+33.0%
Cumulative gain past year
| Period | ABBV Return | S&P 500 |
|---|---|---|
| 1m | +15.0% | +0.3% |
| 3m | +22.1% | +4.7% |
| 6m | +18.7% | +7.5% |
| 1y | +33.0% | +18.4% |
| ytd | +11.0% | +9.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ABBV Fundamental Analysis
Revenue growth is accelerating, with Q1 2026 revenue of $15.002 billion up 12.43% year-over-year, driven by immunology blockbusters Skyrizi ($4.483B) and Rinvoq ($2.119B), which now dominate the portfolio. This marks a significant improvement from the prior year's mid-single-digit growth, as Humira erosion ($688M in Q1 2026) is being more than offset. The multi-quarter trend shows revenue rising from $13.343B in Q1 2025 to $15.002B in Q1 2026, indicating sustained momentum. Profitability remains solid, with Q1 2026 net income of $699 million and a gross margin of 71.88%, though net margin compressed to 4.66% due to higher operating expenses and acquisition-related costs. Operating margin improved to 31.56% from 27.98% a year ago, reflecting operational leverage. The company is profitable, but net income dipped from $1.286B in Q1 2025, partly due to increased R&D spending ($2.472B) and interest expense ($717M). Free cash flow generation is robust, with TTM FCF of $20.865 billion and Q1 2026 FCF of $3.564 billion, easily covering dividends ($3.086B paid) and capex ($265M). The debt-to-equity ratio is negative (-21.12) due to negative shareholder equity, a common issue from large acquisitions, but the current ratio of 0.67x and interest coverage of 6.6x indicate manageable liquidity. ROE is negative (-129.2%) due to negative equity, but ROA of 10.03% shows efficient asset use.
Quarterly Revenue
$15.0B
2026-03
Revenue YoY Growth
+12.4%
YoY Comparison
Gross Margin
71.9%
Latest Quarter
Free Cash Flow
$20.9B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ABBV Overvalued?
Since net income is positive ($699M), the trailing P/E ratio of 96.41x is the primary metric, but this is distorted by low trailing earnings. The forward P/E of 14.99x is more meaningful, implying the market expects significant earnings growth. The gap between trailing and forward P/E (96.41x vs. 14.99x) reflects anticipated margin recovery and EPS expansion from $0.39 in Q1 2026 to an estimated $20.79 for the full year. Compared to the Drug Manufacturers - General industry average P/E of approximately 22x, AbbVie's forward P/E of 14.99x represents a 32% discount, suggesting undervaluation relative to peers. This discount is justified by the company's higher debt load and recent earnings volatility, but its superior growth trajectory (12.4% revenue growth vs. industry ~5%) and strong pipeline support a premium. Historically, AbbVie's trailing P/E has ranged from 15x to over 100x, with the current 96.41x near the top of its historical band due to depressed earnings. However, the forward P/E of 14.99x is near the lower end of its historical range (15x–30x), indicating that the market is pricing in a normalization of earnings, which could offer upside if growth materializes.
PE
96.4x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 15x~139x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
26.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: AbbVie's negative shareholder equity (-21.12 debt-to-equity) and high debt load (interest expense of $717M in Q1 2026) pose financial risk, especially if interest rates remain elevated. The current ratio of 0.67x indicates potential liquidity constraints, though interest coverage of 6.6x provides some cushion. Net income fell to $699M in Q1 2026 from $1.286B a year ago, partly due to increased R&D spending ($2.472B) and acquisition costs, highlighting earnings volatility. The trailing P/E of 96.41x is distorted by low earnings, but the forward P/E of 14.99x assumes significant recovery, which may not materialize if margins compress further.
Market & Competitive Risks: AbbVie's forward P/E of 14.99x is a 32% discount to the industry average, but this discount could widen if growth disappoints or if competitors launch superior therapies. The stock's beta of 0.283 suggests low market correlation, but its recent 30.97% one-year gain may have priced in optimism. Regulatory risks include the FDA rejection of TrenibotE for manufacturing issues, which could delay pipeline contributions. Additionally, the 100% drug tariff policy could impact costs, though AbbVie's domestic manufacturing may mitigate this.
Worst-Case Scenario: In a severe downturn, AbbVie could face a combination of slower Skyrizi/Rinvoq growth, higher debt costs, and regulatory setbacks, driving the stock to its 52-week low of $184.63. This represents a potential 24.4% decline from the current price of $244.11. The analyst low target of $200 implies a 18.1% downside. Historical max drawdown of -19.23% suggests similar magnitude. An investor could lose up to 24.4% in this adverse scenario.
